Almac Makes Further significant Co-Investment to Meet Japanese Client Demand for Humidity Controlled Blister Packaging
Almac has expanded its UK commercial packaging facility, with a significant investment, to provide a state-of-the-art humidity controlled blister packaging suite, complete with off-line “just in time” blister printing.
Meeting the requirements of two Japanese clients, the expansion included extensive suite modifications for processing humidity sensitive drug products; installation of a new Noack 623 blister line, a custom designed desiccant feeder and an off-line Hapa Blister-Jet printer.
The Noack blister line provides enhanced flexibility for processing larger blister sizes and innovative multi-product blister formats; it can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220 mm x 155 mm. This versatile line facilitated the integration of a bespoke desiccant feeder that cuts, picks and places reel-fed desiccant wafers into blister pockets.
The off-line Hapa Blister-Jet augments just-in-time production. By printing country-specific artwork and variable data on each individual blister pocket, it enhances flexibility and significantly reduces stock holding.
James MacKenzie, Commercial Director at Hapa notes: “Almac represents an exciting watermark for Hapa. This partnership indicates that our innovation strategy — with high investment in just-in-time, on demand print technologies is on the right track. As order sizes continue to fall, the business case for late stage customisation continues to grow. The addition of the Blister-Jet to Almac’s portfolio extends their capability to provide rapid and efficient late stage customisation of bulk-packed blisters.” He explained that Almac’s partnership-approach to working with clients is shared by Hapa. “Their expertise,”MacKenzie added, “enables us to deliver this project quickly and efficiently.”
David Downey, Almac’s VP of Commercial Operations explains: “This co-investment allows Almac to address complex packaging challenges associated with innovative drug products that require enhanced environmental controls but, importantly, also provides our partners with the option to address modest country-specific market volumes, by off-line printing blank blisters through the Hapa unit. This solution will be of significant value to those companies launching orphan and niche blistered drug products into EU and ROW markets, many of which Almac already support.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance